Biotech Sees Massive Buying Pressure Following Phase 2 Preliminary Data
13 8월 2024 - 11:50PM
AllPennyStocks.com
A California-based biotech company is finding
early success on Tuesday after the company announced positive
preliminary data of Vebreltinib in patients with non-CNS met
fusion...
To read the full story on AllPennyStocks.com, click
here.
Apollomics (NASDAQ:APLMW)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Apollomics (NASDAQ:APLMW)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024